13F Holdings
中文EN

PLSH PANACEA LIFE SCIENCES HOLDINGS, INC.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1552189 · Fiscal year ends 12/31

Financial factors as of 2023-03-31 (2023Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.7%
TTM net income YoY-3.7%
TTM EPS YoY-14.6%
Revenue 3-yr CAGR19.2%
Net income 3-yr CAGR—

Margins

Gross margin28.4%
Operating margin-288.0%
Net margin-443.5%
FCF margin-137.5%
EBITDA margin-196.4%

Returns

ROE-4,290.8%
ROA-39.8%
ROIC (approx.)-3,336.3%
Asset turnover0.09x

Leverage & solvency

Liabilities / assets120.5%
Debt / equity—
Current ratio0.37x
Interest coverage-2.75x

Cash quality & payout

Operating cash flow / net income0.28x
Accruals ratio-28.7%
Payout ratio—
Capex / revenue13.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2024Q12024-03-312023Q4*2023-12-312023Q32023-09-302023Q22023-06-302023Q12023-03-312022Q4*2022-12-312022Q32022-09-302022Q22022-06-30
Income statement
Revenue$1.06M$960,496$347,851$399,128$677,481$324,788$366,244$469,472
Cost of revenue$390,282$413,561$201,232$196,314$451,872$213,999$318,918$331,500
Gross profit$666,165$546,935$146,619$202,814$225,609$110,789$47,326$137,972
SG&A expense$249,038$787,060$276,726$145,213$257,413$166,628$261,506$204,678
Operating income-$1.06M-$1.77M-$1.41M-$1.07M-$1.29M-$1.38M-$1.39M-$1.24M
Interest expense$429,672$412,194$396,582$366,944$380,157$378,956$597,935$569,985
Pretax income-$1.45M-$2.21M-$2.15M-$1.86M-$1.79M-$1.70M-$2.69M-$1.96M
Net income-$1.45M-$2.21M-$2.15M-$1.86M-$1.79M-$1.70M-$2.69M-$1.96M
EBITDA-$673,850-$1.32M-$990,031-$651,382-$867,409-$946,138-$967,014-$830,107
EPS (basic)-0.09—-0.13-0.11-0.12—-0.18-0.13
EPS (diluted)-0.09—-0.13-0.11-0.12—-0.18-0.13
Weighted avg. shares (diluted)16.49M—16.62M17.65M14.97M—14.86M14.97M
Balance sheet
Cash & equivalents$107,643$100,922$1,495$8,190$73,232$6,951$36,791$36,529
Short-term investments$9,504$14,933$78,420$460,388$925,107$1.11M$1.12M$2.56M
Receivables$270,851$263,970$308,810$272,090$274,787$206,127$221,919$219,551
Inventory$4.06M$4.01M$4.69M$4.36M$4.10M$4.45M$4.41M$4.48M
Current assets$4.64M$4.66M$5.87M$5.75M$5.95M$6.38M$6.48M$8.12M
PP&E, net$6.07M$6.45M$6.87M$6.86M$7.27M$7.68M$7.96M$8.21M
Goodwill$3.01M$3.01M$3.01M$2.19M$2.19M$2.19M$2.19M$2.19M
Intangibles$3.01M$3.01M———$2.19M$15,351$30,701
Total assets$17.41M$17.98M$18.73M$17.85M$18.56M$19.49M$19.98M$21.97M
Current liabilities$20.39M$19.45M$18.54M$17.05M$15.89M$15.07M$13.81M$13.06M
Total liabilities$27.04M$26.27M$24.82M$23.42M$22.36M$21.63M$20.42M$19.71M
Shareholders' equity-$9.62M-$8.29M-$6.08M-$5.57M-$3.80M-$2.14M-$439,907$2.25M
Shares outstanding18.31M17.65M17.65M17.65M15.51M14.97M14.97M14.97M
Cash flow statement
Operating cash flow-$357,090$1,573-$728,869-$483,316-$313,851-$522,999-$711,080-$729,457
Capital expenditure$5,000——$9,350$15,220$98,843$127,357$7,879
Free cash flow-$362,090——-$492,666-$329,071-$621,842-$838,437-$737,336
Investing cash flow-$5,000-$17,905-$22,847-$9,350-$15,220-$98,843-$127,357$38,953
Financing cash flow$368,811$115,759$745,021$427,624$395,352$592,002$838,699$671,036
Depreciation & amortization$383,498$443,647$424,040$422,728$422,554$429,409$421,695$409,895

Free plan shows the latest 8 periods; Pro shows all 40 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.